LGG-52. BINIMETINIB IN CHILDREN WITH PROGRESSIVE OR RECURRENT LOW-GRADE GLIOMA NOT ASSOCIATED WITH NEUROFIBROMATOSIS TYPE 1: INITIAL RESULTS FROM A MULTI-INSTITUTIONAL PHASE II STUDY

BACKGROUND: RAS/RAF/MEK/ERK pathway activation is the primary driver for most pediatric low-grade gliomas (LGG). Binimetinib is an orally bioavailable MEK1/2 inhibitor found to have significant central nervous system penetration in a preclinical model. OBJECTIVE: The primary objective of this multi-...

Descripción completa

Detalles Bibliográficos
Autores principales: Robison, Nathan, Pauly, Jasmine, Malvar, Jemily, Gardner, Sharon, Allen, Jeffrey, MacDonald, Tobey, Aguilera, Dolly, Baxter, Patricia, Bendel, Anne, Kilburn, Lindsay, Leary, Sarah, Bowers, Daniel, Dorris, Kathleen, Gauvain, Karen, Alva, Elizabeth, Cohen, Kenneth, Nazemi, Kellie, Tan, Yi Juin, Margol, Ashley, Dhall, Girish, Rosser, Tena, Davidson, Tom, Plant, Ashley, Ullrich, Nicole, Bandopadhayay, Pratiti, Agar, Nathalie, Ligon, Keith, Sposto, Richard, Wright, Karen, Kieran, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Low Grade Glioma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715340/
http://dx.doi.org/10.1093/neuonc/noaa222.430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715340/
http://dx.doi.org/10.1093/neuonc/noaa222.430

Ejemplares similares